RESULTS

Patient demographics and specimen types
A total of 7881 isolates recovered from clinical specimens were collected from hospitals across Canada; 54.7% (4311 of 7881) of isolates were collected from males while 45.3% (3570 of 7881) were from females. Patient age breakdown was: 17 years or younger, 11.7% (926 of 7881); 18 to 64 years, 47.3% (3726 of 7881); and 65 years and older, 41.0% (3229 of 7881). Organisms were obtained from respiratory specimens (29.3%; 2306 of 7881), blood (46.1%; 3631 of 7881), wounds/tissue (7.8%; 617 of 7881) and urine (16.8%; 1327 of 7881). Table 1 describes the 20 most common organisms isolated in hospitals across Canada. The most common Gram-positive cocci included MSSA, S pneumoniae, MRSA, coagulasenegative staphylococci/Staphylococcus epidermidis and Enterococcus species, which together represented 34.7% of all isolates. The most common Gram-negative bacilli included E coli, P aeruginosa, Klebsiella pneumoniae, Haemophilus influenzae and Enterobacter cloacae, which together made up 41.8% of all organisms from hospitals across Canada. Table 2 describes the 10 most common isolates recovered from clinical specimens from the four specimen sites, including respiratory, blood, wounds/tissue and the urinary tract. Within the respiratory tract, S pneumoniae, MSSA and MRSA were the most common Gram-positive cocci, accounting for 42.4% of isolates. For Gram-negative bacilli, P aeruginosa, H influenzae, E coli, Moraxella catarrhalis, Stenotrophomonas maltophilia, K pneumoniae and Serratia marcescens represented 46.9% of isolates obtained. Among blood culture isolates, Gram-positive cocci, including MSSA, coagulase-negative staphylococci/ S epidermidis, S pneumoniae, MRSA and E faecalis made up 35.8% of organisms isolated in Canadian hospitals. The most common Gram-negative bacilli isolated from blood included E coli, K pneumoniae, P aeruginosa and E cloacae, which made up 35.7% of all isolates. For wounds/tissue, Gram-positive cocci, including MSSA, MRSA, Streptococcus pyogenes, coagulase-negative staphylococci/S epidermidis and Enterococcus species made up 58.7% of the total isolates. The most common Gram-negative bacilli isolated from wounds/tissue were P aeruginosa, E coli, E cloacae and K pneumoniae, which made up 25.7% of all isolates. From the urinary tract the most commonly isolated organisms were Gram-negative bacilli, including E coli, K pneumoniae, Proteus mirabilis, P aeruginosa, E cloacae and Klebsiella oxytoca, which made up 74.7% of isolates. Gram-positive cocci obtained from the urinary tract most commonly included Enterococcus species, coagulase-negative staphylococci/S epidermidis, Streptococcus agalactiae and MSSA, which made up 19.0% of isolates.
Most common organisms isolated in Canadian hospitals
Most common organisms isolated by specimen site
Characteristics of MRSA
Of the 385 MRSA (26.0% of all S aureus) isolated from hospitals in Canada, 19 .5% were CA-MRSA and 79.2% were HA-MRSA, as determined by PFGE; 1.3% of MRSA could not be genotypically classified. CA-MRSA belonged to PFGE types CMRSA10/USA300 (66.7%) and CMRSA7/USA400 (33.3%); PFGE types identified among HA-MRSA included CMRSA2/USA100/800 (81.6%), CMRSA6 (13.1%), CMRSA1/USA600 (3.3%), CMRSA5/USA500 (1.3%), CMRSA3 (0.3%) and CMRSA9 (0.3%). Panton-Valentine leukocidin was detected in 94.7% of CA-MRSA and 0.7% of HA-MRSA. More data on MRSA in CANWARD 2007 are described by Nichol et al (20) in the present supplement.
Characteristics of ESBL E coli
Fifty-three of 1560 (3.4%) E coli were ESBL producers. ESBLproducing E coli ranged from 1.1% in ERs, 1.9% in ICUs, 3 .3% Baudry et al (21) in the present supplement.
Characteristics of VRE
Of the 1.8% VRE (eight of 450 of all Enterococci species) isolated, 62.5% displayed a vanA genotype, while 37.5% displayed a vanB genotype. All VRE were E faecium.
Antimicrobial susceptibility
Antimicrobial resistance rates (per cent of isolates determined to be intermediate and resistant) for the most common Grampositive cocci based on specimen source are listed in Table 3 . With MRSA, no resistance was observed to daptomycin, linezolid, tigecycline and vancomycin. Nitrofurantoin (urinary indication only) proved to be active against MRSA as well, with 0% resistance (Table 3) . Resistance rates with MRSA were: clarithromycin 91.4%, clindamycin 61.8%, fluoroquinolones 88.6% to 89.6%, and trimethoprim-sulfamethoxazole (SXT) 12.2% ( Table 3 ). The lowest rates of resistance with MRSA occurred in wound specimens with clindamycin and SXT ( (Table 3) . With S pneumoniae, no resistance was observed to vancomycin or linezolid. Resistance rates with S pneumoniae were: fluoroquinolones 0.6% to 4.3%, ceftriaxone 0.1%, carbapenems 0.1% to 0.3%, clarithromycin 12.9%, clindamycin 5.7% and SXT 7.0% (Table 3) . Resistance rates for all agents tested were higher in S pneumoniae obtained from respiratory versus blood specimens ( (Table 3 ). Higher resistance for tested agents was observed with E faecium compared with E faecalis including vancomycin, with resistance of 12.0% (Table 3 ). Antimicrobial resistance rates (per cent of isolates determined to be intermediate and resistant) for the most common Gram-positive cocci based on hospital ward location are listed in Table 4 . With S aureus (MSSA), resistance rates for fluoroquinolones, clarithromycin, clindamycin and SXT were not influenced by ward location, with similar rates in hospital clinics, ERs, ICUs, and medical and surgical wards ( Table 4) . Resistance rates with MRSA obtained from the ER were lower versus other hospital areas for fluoroquinolones, clindamycin and SXT (Table 4) . With S pneumoniae, limited differences occurred with beta-lactams, fluoroquinolones and SXT per hospital ward location, likely due to low resistance rates overall for these agents. S pneumoniae resistance with clarithromycin and clindamycin occurred in all hospitals areas (Table 4 ). Gram-negative bacilli based on specimen source are listed in Table 5 . With E coli, no resistance was observed to ertapenem, meropenem and tigecycline ( Table 5 ). Resistance rates with E coli were: amoxicillin-clavulanate 1.2%, cefazolin 14.2%, 0 . 0 5 / a n a n a n a n a n a n a n a n a n a n a n a n a n a n a n a n e n i r U a n a n a n a n a n a n a n a n a n a n a n a n a n a n a n a n d n u o W a n a n a n a n a n a n a n a n a n a n a n a n a n a n a n a n
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a n a n a n -a n --a n a n / 0 a n a n a n a n -a n a n a n a n a n a n a n a n a n a n a n a n a n -a n a n a n a n a n a n a n a n a n a n a n a n a n -a n a n a n a n a n a n a n a n a n a a n a n a n a n -a n a n a n a n a n a n a n a n a n a a n a n a n a n -a n a n a n a n a n a n a n a n a n -a n a n a n -a n a n a n a n a n a n d n u o W a n -a n a n a n -a n a n a n a n a n Table 6 . With E coli and K pneumoniae, resistance rates for penicillins, cephalosporins, fluoroquinolones, aminoglycosides and SXT were highest from medical and surgical ward specimens and lowest in ER specimens (Table 6 ). With P aeruginosa, resistance rates were highest in ICU specimens for penicillins, cephalosporins, carbapenems, fluoroquinolones and colistin (Table 6 ). Aminoglycoside resistance with P aeruginosa was highest in hospital clinics, which included cystic fibrosis clinics ( Table 6) .
MDR
MDR was assessed in Gram-negative organisms only, because no accepted definition exists for Gram-positive organisms ( Table 7) . MDR for Gram-negative organisms was defined as resistance to three or more of the following: cefepime, piperacillin-tazobactam, meropenem, amikacin or gentamicin, and ciprofloxacin (adapted from reference 1). The MDR phenotype was most common in P aeruginosa at 10.6%. A MDR phenotype occurred in 1.2% of E coli, 1.5% of K pneumoniae, and 0% of E cloacae and H influenzae ( Table 7 ).
DISCUSSION
The CANWARD study was the first national, prospective surveillance study assessing antimicrobial resistance in hospitals across Canada. This national surveillance study involving 12 medical centres in major population centres in seven of the 10 provinces in Canada collected isolates from blood, respiratory, wound and urinary specimens. Unlike previous studies that documented that more than one-half of all isolates recovered from clinical specimens in hospitals were from the respiratory tract, the CANWARD study could not make such a conclusion because it was set up to collect isolates from a variety of specimen sources to assess antimicrobial resistance patterns, rather than assessing the prevalence of infectious diseases in Canadian hospitals (1, 3) . It has previously been reported that of the deaths associated with heath care-associated infections in American hospitals (National Nosocomial Infections Surveillance [NNIS], 2002), approximately 36.3% were respiratory, 31.0% were bloodstream, 13.2% were urinary tract and 8.3% were surgical site (wound) infections (22) . We report that the 10 most common isolates recovered from 76.5% of all clinical specimens in hospitals across Canada were E coli, MSSA, S pneumoniae, P aeruginosa, K pneumoniae, MRSA, H influenzae, coagulase-negative staphylococci/S epidermidis, Enterococcus species and E cloacae ( Table 1 ). Our data are in keeping with previous reports that Gram-positive cocci including MSSA, S pneumoniae, MRSA and Enterococcus species are the most common Gram-positive isolates recovered from clinical specimens in North American hospitals (3, 23) . The recent report by Lockhart et al (1) that the most common Gramnegative bacilli isolated from American institutions from 1993 to 2004 were P aeruginosa, E coli, K pneumoniae and E cloacae is also consistent with our findings.
In all hospitals involved in the CANWARD study, MSSA and MRSA were important isolates recovered from clinical specimens including bacteremia, respiratory tract specimens and wound/tissue specimens. MRSA made up 26.0% of all staphylococci and, surprisingly, 19.5% of all MRSA in Canadian hospitals were CA-MRSA. In a previous study involving 19 ICUs across Canada (3), we reported that 9.1% of all MRSA were CA-MRSA. Thus, it is clear that CA-MRSA genotypes are rapidly spreading across Canadian hospitals. The most common CA-MRSA genotypes continue to be CMRSA10/ USA300 (66.7%) and CMRSA7/USA400 (33.3%), which is consistent with previous reports (4, 11, 13, 15) . The most common HA-MRSA genotypes in Canadian hospitals were CMRSA2/USA100/800 (81.6%) and CMRSA6 (13.1%), which has also been previously documented (4, 11, 13, 15) . The CANWARD study also showed that VRE made up only 1.8% of all enterococci with the vanA genotype (mostly E faecium) making up 62.5% of all VRE. The present study, as well as previous work, confirms that E faecium carrying vanA is the predominant genotype in North America (10, 11, 19) . The low level of VRE across Canada has been previously documented and shows the lack of spread of VRE across the country (10, 11) . Whether the low level of VRE in Canadian hospitals reflects the use of active surveillance programs, which have been reported to prevent VRE colonization and bacteremia, is unknown (24, 25) . A recent Australian study has reported that aggressive hand hygiene does not only reduce the incidence of MRSA infections but can also lower MRSA bacteremia (26) .
The CANWARD study found that 3.4% of E coli were ESBL producers. Most concerning was that ESBL-producing E coli were isolated from all hospital areas (ie, ERs, ICUs, hospital clinics, and medical and surgical wards). In addition, because ESBL-producing E coli were identified in 11 of the 12 sites, and because 90.6% of the isolates displayed an MDR phenotype, it is strongly suspected that MDR ESBL-producing E coli are now firmly established in Canadian hospitals. This study showed that the CTX-M genotype (bla CTX-M-15 and bla CTX-M-14 ) was the predominant genotype in Canadian hospitals. Other studies assessing ESBL-producing E coli have shown that the CTX-M genotype is spreading rapidly in both community and hospital settings (5, 7, 8, 11, 18, 27, 28) The present study showed that with the exception of MRSA, where resistance to fluoroquinolones, clindamycin and SXT was lower in the ER compared with other hospital locations, little differences in resistance rates with Gram-positive cocci were observed among various hospital locations. This is consistent with previous studies where higher resistance rates in the ICU as well as medical and surgical wards have been reported with Gram-negative bacilli but not Gram-positive cocci (1, 3, 29, 30) . In agreement with previous studies, we found that resistance rates with E coli and K pneumoniae were highest from medical and surgical ward specimens and lowest in ER specimens, whereas with P aeruginosa, resistance rates were highest in the ICU (1,3,30 ). The reason that resistance rates were high in clinics is because these primarily represented hospital specialty clinics such as cystic fibrosis clinics rather than acute care outpatient clinics.
With MRSA, resistance rates were very high with fluoroquinolones, macrolides (such as clarithromycin) and clindamycin, but lower with SXT (12.2%). These resistance rates are consistent with previous reports (3, 15) . Thus, SXT still represents a reasonable empirical treatment for mild to moderate infections (eg, skin and soft tissue infections) caused by CA-MRSA or HA-MRSA. All MRSA were susceptible to vancomycin, linezolid, tigecycline and daptomycin. It should be stated that even though only four of 385 (1.0%) MRSA demonstrated vancomycin MICs of 2 µg/mL, unlike others, we did not assess the prevalence of heteroresistant vancomycinintermediate S aureus by population analysis profiling (31) . A recent analysis from Detroit identified 8.3% (of 917 strains assessed from 2003 to 2007) of MRSA as heteroresistant vancomycin-intermediate S aureus (31) . All MRSE were susceptible to vancomycin, linezolid, tigecycline and daptomycin, while no Enterococcus species proved to be resistant to tigecycline or daptomycin. The lowest rates of resistance for Gramnegative bacilli occurred with amikacin, cefepime, ertapenem (except P aeruginosa), meropenem and piperacillin-tazobactam, which is consistent with previous reports (1, 3, 30) . The low resistance with amikacin likely reflects the low usage of aminoglycosides in favour of the fluoroquinolones in Canada and the United States over the past decade. In contrast, fluoroquinolone resistance was high with E coli (23.6% to 24.5%) and P aeruginosa (23.4% to 25.1%), which is consistent with other reports (1, 3, 30) , and reflects extensive fluoroquinolone usage (27) . A recent report documented increasing prevalence of MDR Gram-negative bacilli in American ICUs (1) . Although our definition of MDR for Gram-negative bacilli (resistance to three or more of the following: cefepime, piperacillin-tazobactam, meropenem, amikacin or gentamicin, and ciprofloxacin), was slightly more restrictive, our MDR rates of 10.6% with P aeruginosa were somewhat higher than previously reported in the United States, at 9.3% (1). In contrast, MDR rates in Canadian hospitals of 1.2% with E coli, 0% with E cloacae, and 1.5% with K pneumoniae are lower than those in American institutions at 2.0%, 5.9% and 13.3%, respectively. Why MDR rates are higher in Canada with P aeruginosa and lower with Enterobacteriaceae (E coli, E cloacae and K pneumoniae) is unclear, but may be due to the lower prevalence of ESBLproducing Enterobacteriaceae in Canada (3, 11) . MDR ESBLproducing E coli were all susceptible to the carbapenems, ertapenem and meropenem, as well as tigecycline.
The limitations of the CANWARD study are numerous, including the fact that we cannot be certain that all clinical specimens represented active infection. As in our previous CAN-ICU study (3, 11) , we asked centres to obtain "clinically significant" specimens from patients with a presumed infectious disease. Although all of the isolates may not represent actual infection from patients, we believe that most do because we excluded all surveillance swabs, duplicate swabs, eye, ear, nose and throat swabs, and genital cultures. Another limitation is that we do not have admission date data for each patient and clinical specimen, thus were not able to provide a more accurate description of community versus nosocomial onset. In the present study, CA-MRSA and HA-MRSA were defined genotypically and not epidemiologically. Any MRSA with a CMRSA-7 (USA400/MW2) or CMRSA-10 (USA300) genotype were labelled as CA-MRSA while all other genotypes (eg, CMRSA-1 [USA600], CMRSA-2 [USA100], CMRSA-4 [USA200]) were labelled as HA-MRSA. It is known epidemiologically that CA-MRSA genotypes can be associated with health care-associated infections and that HA-MRSA can be associated with community-associated infections (13) . E coli and K pneumoniae were screened for potential ESBL production using only ceftriaxone, which, although consistent with CLSI guidelines, may have missed some SHV-producing K pneumoniae strains by not also testing ceftazidime. Whether this accounted for the reduced number of ESBL-producing K pneumoniae versus ESBL-producing E coli is unclear. Finally, susceptibility testing was not performed for all antimicrobial agents due to lack of space on the susceptibility panels utilized. It is recognized that data on antimicrobials such a ceftazidime, imipenem, tobramycin and others would be beneficial, because different hospital formularies stock these and other antimicrobials not tested in the present study.
CONCLUSIONS
E coli, S aureus (MSSA and MRSA), S pneumoniae, P aeruginosa, K pneumoniae, H influenzae and Enterococcus species are the most common isolates recovered from clinical specimens in Canadian hospitals. The prevalence of MRSA was 26.0% (of which genotypically, 19.5% was CA-MRSA), VRE 1.8% and ESBL-producing E coli 3.4% of isolates. A MDR phenotype is common with P aeruginosa in Canadian hospitals.
